Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to -$3.6 million.

  • Lineage Cell Therapeutics' Free Cash Flow rose 3849.81% to -$3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.9 million, marking a year-over-year increase of 945.96%. This contributed to the annual value of -$23.7 million for FY2024, which is 1909.37% up from last year.
  • According to the latest figures from Q3 2025, Lineage Cell Therapeutics' Free Cash Flow is -$3.6 million, which was up 3849.81% from -$5.6 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Free Cash Flow high stood at $21.9 million for Q1 2022, and its period low was -$11.4 million during Q1 2023.
  • Moreover, its 5-year median value for Free Cash Flow was -$5.8 million (2024), whereas its average is -$4.8 million.
  • In the last 5 years, Lineage Cell Therapeutics' Free Cash Flow soared by 39398.79% in 2022 and then crashed by 15229.21% in 2023.
  • Over the past 5 years, Lineage Cell Therapeutics' Free Cash Flow (Quarter) stood at -$6.0 million in 2021, then tumbled by 37.68% to -$8.3 million in 2022, then increased by 26.27% to -$6.1 million in 2023, then fell by 9.84% to -$6.7 million in 2024, then skyrocketed by 45.94% to -$3.6 million in 2025.
  • Its last three reported values are -$3.6 million in Q3 2025, -$5.6 million for Q2 2025, and -$5.0 million during Q1 2025.